Immunomodulation by HLA class I-derived peptides.
Synthetic peptides corresponding to linear sequences of HLA class I molecules have profound immunomodulatory effects in vitro and in vivo. Recent clinical trials confirm their potential as the therapeutics for transplantation and for a variety of immune-mediated diseases. These peptides also inhibit NK responses in vivo in humans. The importance of the carboxy end of the alpha 1 alpha helix in negative signaling to both T cells and NK cells focuses attention on new targets for immunotherapy.
Krensky
A M
AM
Department of Pediatrics, Stanford University School of Medicine, California 94305-5119, USA.
Clayberger
C
C
D000595:Amino Acid Sequence; D000818:Animals; D002986:Clinical Trials as Topic; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D015789:HLA-A2 Antigen / Q000737:chemistry / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology; D010446:Peptide Fragments / Q000737:chemistry / Q000627:therapeutic use*; D017433:Protein Structure, Secondary; D011948:Receptors, Antigen, T-Cell / Q000737:chemistry / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D015789:HLA-A2 Antigen; D015395:Histocompatibility Antigens Class I; D010446:Peptide Fragments; D011948:Receptors, Antigen, T-Cell